WHAT DOES ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC) MEAN?

These side effects were notably milder as compared to an inhibitor of equally bromodomains. An in depth molecular Assessment also unveiled that ABBV-744 preferentially inhibits the expression of Androgen Receptor (AR)-dependent genes.  ― Stephen TaylorFor all stream cytometry experiments, 10,000 cells for every replicate had been analyzed, and a